AbCellera Biologics Inc.

AbCellera Biologics Inc. (ABCL) priced its initial public offering on Dec 14, 2020 at $20.00 per share, above its $17.00–$18.00 range, raising $483M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $5.31B. Credit Suisse was lead-left underwriter, joined by Stifel, Leerink Partners and BMO Capital Markets. Goodwin Procter, Blake, Cassels & Graydon and Cassels advised the company and Cooley and Osler advised the underwriters.

AbCellera Biologics Inc. runs an AI-powered drug discovery platform that searches the database of natural immune systems to find antibodies that can be developed as drugs. Rather than advancing its own clinical pipeline, it forms partnerships with drug developers ranging from large pharmaceutical companies to small biotechs.

Status

IPO

Ticker

ABCL

Exchange

Nasdaq Global Select

Priced

Dec 14, 2020

IPO price

$20.00

Price range

$17.00–$18.00

Raised

$483M

Market cap at IPO price

$5.31B

First filed

Nov 20, 2020

Underwriters

Credit Suisse, Stifel, Leerink Partners and BMO Capital Markets

Company counsel

Goodwin Procter, Blake, Cassels & Graydon and Cassels

Underwriters' counsel

Cooley and Osler

Sector

Biotech & pharma

Country / state

British Columbia, Canada

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.